These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12639178)

  • 1. Effect of cyclooxygenase-2 inhibitors on blood pressure.
    Johnson DL; Hisel TM; Phillips BB
    Ann Pharmacother; 2003 Mar; 37(3):442-6. PubMed ID: 12639178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 3. The new NSAIDs: cox-2 inhibitors.
    Capriotti T
    Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
    Patrignani P
    Acta Otorhinolaryngol Ital; 2003 Aug; 23(4 Suppl 74):13-8, 37-40. PubMed ID: 15058604
    [No Abstract]   [Full Text] [Related]  

  • 5. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
    Rioda WT; Nervetti A
    Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on specific COX-2 inhibitors: the COXIBs.
    Gupta S; Crofford LJ
    Bull Rheum Dis; 2001; 50(1):1-4. PubMed ID: 12092091
    [No Abstract]   [Full Text] [Related]  

  • 8. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
    Becker RV; Burke TA; McCoy MA; Trotter JP
    Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New anti-inflammatory analgetics--are they needed?].
    Paakkari I
    Duodecim; 1999; 115(20):2217-24. PubMed ID: 11973925
    [No Abstract]   [Full Text] [Related]  

  • 12. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy with preferential and specific COX-2 inhibitors].
    Stichtenoth DO; Frölich JC
    Internist (Berl); 2001 Mar; 42(3):421-6. PubMed ID: 11277028
    [No Abstract]   [Full Text] [Related]  

  • 14. COX-2-specific inhibition: implications for clinical practice.
    Pascucci RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
    Patrono C; Patrignani P; García Rodríguez LA
    J Clin Invest; 2001 Jul; 108(1):7-13. PubMed ID: 11435450
    [No Abstract]   [Full Text] [Related]  

  • 16. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.
    Mazario J; Gaitan G; Herrero JF
    Neuropharmacology; 2001 Jun; 40(7):937-46. PubMed ID: 11378164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The coxibs, third generation anti-inflammatories].
    Sternon J
    Rev Med Brux; 2001 Apr; 22(2):100-5. PubMed ID: 11388024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.